Department of Urology, International St. Mary's Hospital, Catholic Kwandong University, Incheon, South Korea.
Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Pathol Oncol Res. 2021 Apr 13;27:629489. doi: 10.3389/pore.2021.629489. eCollection 2021.
To evaluate the clinicopathological characteristics of grade group 1 (GG1) prostate cancer in Korean populations. We retrospectively analyzed 492 consecutive radical prostatectomy specimens from our institution, which included those from 322 men with clinical GG1 and 170 with clinical GG2 tumors between years 2009 and 2018. The incidence of Gleason score (GS) upgrading, extraprostatic extension (EPE), and seminal vesicle invasion (SVI) were evaluated in patients with clinical GG1. In pathological GG1 cases, the distribution of adverse pathological features including EPE, lymphovascular invasion (LVI), perineural invasion (PNI), and biochemical recurrence (BCR) was analyzed. Altogether, 78 (24.2%) out of 322 men in the clinical GG1 group demonstrated upgrading of GS, including 19 men with pathological Gleason score 4 + 3 = 7 and 6 with ≥ pathological Gleason score 4 + 4 = 8 cases. EPE was found in 37 (11.5%) and 22 (8.9%) men in clinical GG1 and pathological GG1 group, respectively. The incidence of LVI and PNI in the pathological GG1 cases was 2.8% (n = 7) and 28.6% (n = 71), respectively. BCR was observed in 4 men in pathological GG1 T2 (n = 226) and 2 men in GG1 T3 (n = 22) group. When we compared the pathological features between pathological GG1 T3 vs. GG2 T2, there was no statistical differences in the incidence of LVI and PNI between the two groups. Contrary to the current concept that GG1 is almost always clinically insignificant, it seems that GG1 still possess its respectable position as a group of cancer with aggressiveness. These findings should be kept in mind when deciding on treatment options for prostate cancer patients in the Asian populations.
为了评估韩国人群中 1 级（GG1）前列腺癌的临床病理特征。我们回顾性分析了我院 492 例连续根治性前列腺切除术标本，其中包括 322 例临床 GG1 肿瘤和 170 例临床 GG2 肿瘤患者，时间范围为 2009 年至 2018 年。评估了临床 GG1 患者中 Gleason 评分（GS）升级、前列腺外扩展（EPE）和精囊侵犯（SVI）的发生率。在病理 GG1 病例中，分析了包括 EPE、脉管侵犯（LVI）、神经周围侵犯（PNI）和生化复发（BCR）在内的不良病理特征的分布。在临床 GG1 组的 322 名男性中，共有 78 名（24.2%）出现 GS 升级，其中 19 名男性病理 GS 为 4+3=7，6 名男性病理 GS≥4+4=8。临床 GG1 和病理 GG1 组分别有 37（11.5%）和 22（8.9%）名男性发生 EPE。病理 GG1 病例中 LVI 和 PNI 的发生率分别为 2.8%（n=7）和 28.6%（n=71）。在病理 GG1 T2（n=226）组中观察到 4 名男性发生 BCR，在 GG1 T3（n=22）组中观察到 2 名男性发生 BCR。当我们比较病理 GG1 T3 与 GG2 T2 之间的病理特征时，两组之间 LVI 和 PNI 的发生率没有统计学差异。与当前 GG1 几乎总是临床无意义的概念相反，似乎 GG1 仍然具有其作为一组具有侵袭性的癌症的可敬地位。在决定亚洲人群前列腺癌患者的治疗方案时，应牢记这些发现。
